DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 
This case report presents real-world evidence of tralokinumab efficacy in two biologic-naive skin of color patients with moderate-to-severe atopic dermatitis. The study addresses critical gaps in clinical trial diversity and provides valuable insights into rapid treatment response in underrepresented patient populations.
⚕️ Key Clinical Considerations ⚕️
- Rapid onset demonstrated: Both patients achieved IGA reduction from 3 to 1 within 6-10 weeks, with BSA improvements from 22% to 7% and 29% to 6% respectively.
- Head/neck efficacy: Significant improvement observed in difficult-to-treat head and neck regions where long-term topical corticosteroids are contraindicated due to atrophy risks.
- Hyperpigmentation response: Notable improvement in post-inflammatory hyperpigmentation on dorsal hands, addressing a common concern in skin of color patients.
- Sustained efficacy: Clinical improvements maintained throughout 6-month follow-up period with no reported adverse events in either patient.
- Combination therapy: Both patients continued topical corticosteroids during tralokinumab treatment, following standard of care protocols for optimal outcomes.
🎯 Clinical Practice Impact 🎯
- Patient Communication: Provides reassuring real-world data for counseling skin of color patients about tralokinumab’s rapid onset and sustained efficacy, particularly for head/neck involvement.
- Practice Integration: Supports tralokinumab as first-line biologic option for moderate-to-severe AD, especially when dupilumab contraindicated or head/neck involvement present.
- Risk Management: No adverse events reported during 6-month follow-up, though case report limitations prevent comprehensive safety assessment.
- Action Items: Consider tralokinumab for biologic-naive patients with head/neck AD or post-inflammatory hyperpigmentation concerns; maintain topical corticosteroid co-therapy.
More in Dermatology
